()Patient eligibility

Patients who have record to receive fractional photothermosysis therapy (FRAXEL) at Chang
Gung Memorial Hospital are included into our study. Patients with moderate to severe atrophic
acne scars are enrolled in this study. Their ages should be above 20 to 60 years old and their
Fitzpatrick skin types were IVV. Exclusion criteria included known photosensitivity, history of
hypertrophic or keloidal scarring, scabies, and the use of isotretinoin or other physical acne
treatments over the past 3 months. Patients who had any medical illness that could influence the
wound healing process were also excluded. Ten patients, including 10 males and 10 females, will
be enrolled. Written informed consent should be obtained from each patient before treatment.
()
This is a single-center, prospective, double- blind, randomized, placebo- controlled, cross-over
study to evaluate the therapeutic effect of topical calcium on symptom after fractional
photothermolysis surgery, including oedema, prolonged erythema, possible scarring, and
hyperpigmentation in patients. Patients are randomly collect from fractional photothermolysis
treatment course. A 1550-nm Erbium:YAG laser is delivered to the areas at a fluence of 30-40
mJ/MTZ, a total density of 7501500 MTZ/cm2. Treatment parameters were adjusted based on
the scar severity and each patients tolerability. Forced air-cooling was used throughout the
treatment to improve patients comfort and compliance.
Baseline TEWL, PIH are accessed via Multi Dermascope MDS800 and self-assessment of
post-treatment recovery before and after the treatment periods on day 1st, 3rd, 7thday, 1st month,
end up at 3rd month. Patients treat with DERMESIS Toner/Cream on left face and patients in treat
with placebo lotion (w/o Calcium-T) on right face. The first two days after surgery, treat with
only normal inflammation-reducing ointment, and treat DERMESIS or placebo from the third
day to following one month after surgery. Patients applied topical DERMESIS or placebo lotion
in a double-blind fashion to their surgery sites for 2 times a day. The amount of topical lotion
(DERMESIS or placebo lotion) is standardized for each enrolled patient. The amount of topical
lotion initially is 20 mL/d and subsequently is adjusted according to the application area. Topical
lotion is stored in a plastic container for each patients use. Placebo lotion is composed mainly of
the moisture-preserving substance urea. Therapeutic outcomes were assessed by standardized
digital photography, Multi Dermascope MDS800, and patients self-assessment of treatment
outcome.
Besides, the skin barrier function is evaluated by Multi Dermascope MDS800 (Multi
Dermascope MDS800, manufacturing by Dutech Scientific, Germany). We measure the
baseline TEWL/PIH and TEWL/PIH after using DERMESIS. The patient must stay in a closed
space for at least 20 minutes, and the relative humidity of the closed space is 50% 10%, and
temperature is 20 5. The probe is applied to the skin surface of forearm and the water vapor
pressure gradient is measured. The self-assessed level of improvement from the patients was
evaluated using the following five-point scale: 0:no change; 1:slight improvement (025%);
2:moderate improvement (2650%); 3:significant improvement (5175%); 4:excellent
improvement (75-100%)